Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Introduction

In this case report, we present positive psychotic symptoms that developed after low-dose (5 mg/day) escitalopram treatment in a 16-year-old female adolescent with a peroxisome biogenesis disorder.

Case presentation

Two weeks after starting escitalopram treatment for depression, the patient experienced vomiting attacks several times a day. About 2-3 days after the attacks began, the family stopped administering escitalopram. Five days after the onset of vomiting and 2-3 days after stopping escitalopram, the patient developed visual and auditory hallucinations and persecutory delusions. During the patient's follow-up period, the diversity of her hallucinations and delusions increased. When olanzapine treatment was gradually increased to 20 mg/day, the patient's psychotic symptoms disappeared.

Conclusion

We discuss serotonin syndrome, drug-induced bipolar disorder, and psychotic disorder in the differential diagnosis. We believe that this case report is valuable as it is the first in the literature regarding the development of positive psychotic symptoms after SSRI use in a patient with a peroxisome biogenesis disorder.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/0122115560310023240823103145
2024-09-06
2025-06-23

  • From This Site

    /content/journals/cpsp/10.2174/0122115560310023240823103145
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BerendseK. EngelenM. FerdinandusseS. Zellweger spectrum disorders: Clinical manifestations in patients surviving into adulthood.J. Inherit. Metab. Dis.20163919310610.1007/s10545‑015‑9880‑226287655
     [Google Scholar]
  2. KlouwerF.C.C. BerendseK. FerdinandusseS. WandersR.J.A. EngelenM. Poll-TheB.T. Zellweger spectrum disorders: Clinical overview and management approach.Orphanet J. Rare Dis.201510115110.1186/s13023‑015‑0368‑926627182
     [Google Scholar]
  3. Poll-TheB.T. SaudubrayJ.M. OgierH.A. Infantile Refsum disease: An inherited peroxisomal disorder. Comparison with Zellweger syndrome and neonatal adrenoleukodystrophy.Eur. J. Pediatr.1987146547748310.1007/BF004415982445576
     [Google Scholar]
  4. WaterhamH.R. EbberinkM.S. Genetics and molecular basis of human peroxisome biogenesis disorders.Biochim. Biophys. Acta Mol. Basis Dis.2012182291430144110.1016/j.bbadis.2012.04.00622871920
     [Google Scholar]
  5. BravermanN.E. D’AgostinoM.D. MacLeanG.E. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives.Dev. Disabil. Res. Rev.201317318719610.1002/ddrr.111323798008
     [Google Scholar]
  6. WandersR.J.A. WaterhamH.R. Biochemistry of mammalian peroxisomes revisited.Annu. Rev. Biochem.200675129533210.1146/annurev.biochem.74.082803.13332916756494
     [Google Scholar]
  7. BowenP. LeeC.S. ZellwegerH. LindenbergR. A familial syndrome of multiple congenital defects.Bull. Johns Hopkins Hosp.196411440241414169466
     [Google Scholar]
  8. KhoddamS. KamalN. ShiriA. Two siblings with PEX11B-related peroxisome biogenesis disorder.Eur. J. Med. Genet.20246810492810.1016/j.ejmg.2024.10492838423277
     [Google Scholar]
  9. LiJ.J. KimJ.J. NausheenF. Phytanic acid intake and lifestyle modifications on quality of life in individuals with adult refsum disease: A retrospective survey analysis.Nutrients20231511255110.3390/nu1511255137299514
     [Google Scholar]
  10. OmarS.J. RobinsonD. DaviesH.D. MillerT.P. TinklenbergJ.R. Fluoxetine and visual hallucinations in dementia.Biol. Psychiatry199538855655810.1016/0006‑3223(95)00195‑M8562668
     [Google Scholar]
  11. BourgeoisJ.A. ThomasD. JohansenT. WalkerD.M. Visual hallucinations associated with fluoxetine and sertraline.J. Clin. Psychopharmacol.199818648248310.1097/00004714‑199812000‑000129864082
     [Google Scholar]
  12. MowlaA. KhosravizadeganF. EbrahimiA.A. SabayanB. PaniA. Citalopram associated with complex visual hallucination, a case report.Prog. Neuropsychopharmacol. Biol. Psychiatry200933357557610.1016/j.pnpbp.2009.01.01119439248
     [Google Scholar]
  13. LaiC.H. Escitalopram-related visual and auditory hallucination in a non-dementia patient with depression.J. Neuropsychiatry Clin. Neurosci.2012244E1910.1176/appi.neuropsych.1110023923224467
     [Google Scholar]
  14. MoorthyS. ArthurP. Visual and auditory hallucinations associated with escitalopram in a young male.J. Med. Res.20184625625710.31254/jmr.2018.4601
     [Google Scholar]
  15. KrynickiC.R. UpthegroveR. DeakinJ.F.W. BarnesT.R.E. The relationship between negative symptoms and depression in schizophrenia: A systematic review.Acta Psychiatr. Scand.2018137538039010.1111/acps.1287329532909
     [Google Scholar]
  16. StraussG.P. CohenA.S. A transdiagnostic review of negative symptom phenomenology and etiology.Schizophr. Bull.201743471271910.1093/schbul/sbx06628969356
     [Google Scholar]
  17. RichterJ. HölzL. HesseK. WildgruberD. KlingbergS. Measurement of negative and depressive symptoms: Discriminatory relevance of affect and expression.Eur. Psychiatry201955232810.1016/j.eurpsy.2018.09.00830384108
     [Google Scholar]
  18. MistryM. ChandrakarV.R. RajputH.S. Escitalopram induced serotonin syndrome: A case report.Indian J Pharm Prac20191234210.5530/ijopp.12.3.42
     [Google Scholar]
  19. DunkleyE.J.C. IsbisterG.K. SibbrittD. DawsonA.H. WhyteI.M. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity.QJM200396963564210.1093/qjmed/hcg10912925718
     [Google Scholar]
  20. MartinA. YoungC. LeckmanJ.F. MukonoweshuroC. RosenheckR. LeslieD. Age effects on antidepressant-induced manic conversion.Arch. Pediatr. Adolesc. Med.2004158877378010.1001/archpedi.158.8.77315289250
     [Google Scholar]
  21. BaldessariniR.J. FaeddaG.L. OffidaniE. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: A review.J. Affect. Disord.2013148112913510.1016/j.jad.2012.10.03323219059
     [Google Scholar]
  22. DumluK. OrhonZ. ÖzerdemA. TuralÜ. UlaşH. TuncaZ. Treatment-induced manic switch in the course of unipolar depression can predict bipolarity: Cluster analysis based evidence.J. Affect. Disord.20111341-39110110.1016/j.jad.2011.06.01921742381
     [Google Scholar]
  23. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders.Washington, D.CAmerican Psychiatric Association Publishing2013
     [Google Scholar]
/content/journals/cpsp/10.2174/0122115560310023240823103145
Loading

  • Article Type:     Case Report
Keyword(s): bipolar disorder; escitalopram; Peroxisome biogenesis disorders; psychosis; SSRI; zellweger spectrum disorders

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test